Barclays
ACRV icon

Barclays’s Acrivon Therapeutics ACRV Stock Holding History

Barclays’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.26K Sell
5,940
-18,462
-76% -$32.2K ﹤0.01% 4725
2025
Q4 		$58.8K Buy
24,402
+4,437
+22% +$9.64K ﹤0.01% 4713
2025
Q3 		$36.1K Sell
19,965
-960
-5% -$1.35K ﹤0.01% 4846
2025
Q2 		$24.9K Sell
20,925
-11,773
-36% -$16.2K ﹤0.01% 4816
2025
Q1 		$66.4K Sell
32,698
-5,393
-14% -$29K ﹤0.01% 4533
2024
Q4 		$229K Buy
38,091
+4,785
+14% +$34.8K ﹤0.01% 4243
2024
Q3 		$233K Buy
33,306
+11,273
+51% +$88.8K ﹤0.01% 4219
2024
Q2 		$128K Buy
22,033
+709
+3% +$5.71K ﹤0.01% 3790
2024
Q1 		$152K Sell
21,324
-3,160
-13% -$14.7K ﹤0.01% 4248
2023
Q4 		$120K Buy
24,484
+10,384
+74% +$54.8K ﹤0.01% 4593
2023
Q3 		$135K Sell
14,100
-163
-1% -$1.88K ﹤0.01% 3476
2023
Q2 		$185K Sell
14,263
-2,720
-16% -$32.9K ﹤0.01% 3283
2023
Q1 		$216K Buy
16,983
+12,841
+310% +$216K ﹤0.01% 3745
2022
Q4 		$47.7K Buy
+4,142
New +$52.6K ﹤0.01% 4569

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's ACRV Position: Q1 2026 in Review

Barclays reduced its Acrivon Therapeutics (ACRV) stake by 76% in Q1 2026, selling an estimated $32.2K and leaving 5,940 shares worth $8.26K. The position accounts for ﹤0.01% of the portfolio, ranked #4725.

Barclays first reported a position in ACRV in Q4 2022 and has held it in 14 quarters since. The position peaked at $233K in Q3 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Barclays held 5,940 shares of Acrivon Therapeutics worth $8.26K as of Q1 2026.
  • Barclays sold 18,462 Acrivon Therapeutics shares in Q1 2026, an estimated $32.2K.
  • Acrivon Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4725 holding.
  • Barclays first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Barclays's Acrivon Therapeutics position peaked at $233K in Q3 2024.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.